Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
6.50
+0.13 (2.04%)
Dec 5, 2025, 4:00 PM EST - Market closed
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
1.57B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SVRA News
- 3 days ago - Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System - Business Wire
- 15 days ago - Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
- 19 days ago - Savara: A High-Risk Opportunity - Seeking Alpha
- 23 days ago - Savara Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 4 weeks ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA - GlobeNewsWire
- 5 weeks ago - Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M - Business Wire
- 5 weeks ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - GlobeNewsWire
- 5 weeks ago - Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants - Business Wire